543 related articles for article (PubMed ID: 29554495)
41. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
42. Advances in Therapeutic Cancer Vaccines.
Wong KK; Li WA; Mooney DJ; Dranoff G
Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
[TBL] [Abstract][Full Text] [Related]
43. Bispecific T-cell engagers for cancer immunotherapy.
Huehls AM; Coupet TA; Sentman CL
Immunol Cell Biol; 2015 Mar; 93(3):290-6. PubMed ID: 25367186
[TBL] [Abstract][Full Text] [Related]
44. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
45. Whole cell vaccines--past progress and future strategies.
Keenan BP; Jaffee EM
Semin Oncol; 2012 Jun; 39(3):276-86. PubMed ID: 22595050
[TBL] [Abstract][Full Text] [Related]
46. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
47. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
48. Poxvirus-based vaccines for cancer immunotherapy: new insights from combined cytokines/co-stimulatory molecules delivery and "uncommon" strains.
Izzi V; Buler M; Masuelli L; Giganti MG; Modesti A; Bei R
Anticancer Agents Med Chem; 2014 Feb; 14(2):183-9. PubMed ID: 24237219
[TBL] [Abstract][Full Text] [Related]
49. [Dendrite cell-based cancer vaccines--clinical application].
Svane IM; Berntsen A; Trepiakas R; Pedersen AE
Ugeskr Laeger; 2006 Apr; 168(14):1415-20. PubMed ID: 16584668
[TBL] [Abstract][Full Text] [Related]
50. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
51. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.
Mellman I; Hubbard-Lucey VM; Tontonoz MJ; Kalos MD; Chen DS; Allison JP; Drake CG; Levitsky H; Lonberg N; van der Burg SH; Fearon DT; Wherry EJ; Lowy I; Vonderheide RH; Hwu P
Cancer Immunol Res; 2016 Apr; 4(4):279-88. PubMed ID: 27036972
[TBL] [Abstract][Full Text] [Related]
52. Tumor vaccine: current trends in antigen specific immunotherapy.
Baral R
Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
[TBL] [Abstract][Full Text] [Related]
53. Methods for improving the immunogenicity and efficacy of cancer vaccines.
Pilla L; Ferrone S; Maccalli C
Expert Opin Biol Ther; 2018 Jul; 18(7):765-784. PubMed ID: 29874943
[TBL] [Abstract][Full Text] [Related]
54. Current status and future prospects of peptide-based cancer vaccines.
Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
[TBL] [Abstract][Full Text] [Related]
55. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
Ikeda H; Shiku H
Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
[TBL] [Abstract][Full Text] [Related]
56. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
57. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
[TBL] [Abstract][Full Text] [Related]
58. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
59. Contemporary immunotherapy of solid tumors: from tumor-associated antigens to combination treatments.
Spagnoli GC; Ebrahimi M; Iezzi G; Mengus C; Zajac P
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):184-92. PubMed ID: 20205052
[TBL] [Abstract][Full Text] [Related]
60. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
Shurin MR; Gregory M; Morris JC; Malyguine AM
Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
